Nascent Biotech Inc. (NBIO)

[Billydakidd]

Nascent Biotech, Inc. is a biotechnology company developing proprietary human Monoclonal Antibodies (mAbs) and immunotherapy for treatment of cancer.

Our development strategy involves pursuing a novel target not being explored by other companies;

developing broad pipeline including therapies and diagnostics against the antigen, and platform drug delivery technology.

Our lead therapeutic asset, Pritumumab, has been validated in 249 human brain cancer patients.

Some of our achieved milestones include:

Re-engineered antibody into CHO cells; created and fully characterized
Master Cell Bank (MCB) in accord with FDA requirements
Developed scale-up CGMP-compliant manufacturing process; production of material for human clinical trials

Presented new clinical plan to FDA in pre-IND (Investigational New Drug) meeting
Successfully completed Toxicology studies

Secured NIH funding for novel “second generation” platform in collaboration with

MAPP Biopharma

Granted Orphan Drug Designation

Cleared IND 12/2018

Approved IRB 11/2019